However, the EGFR mutation rates in the patients who underwent Neoadj-Chemo dropped to 33.3% (9/27) in adenocarcinoma and 8.57% (3/35) in squamous cell carcinoma, with a non-significant difference (P>0.05). The gene discussed is EGFR; the disease is adenocarcinoma.